Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384695364> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4384695364 abstract "Programmed cell death-1 (PD-1) and its ligand 1 (PD-L1) inhibitors have achieved good efficacy and safety in patients with advanced EGFR mutation-negative non-small cell lung cancer (NSCLC), but their efficacy in patients with previous EGFR mutations is limited. The aim of the present study was to explore the efficacy of PD-1/L1 immune checkpoint inhibitors for the treatment of patients with advanced NSCLC who are resistant to EGFR-TKIs.This retrospective study included 123 patients with stage IV NSCLC who received treatment in Shanghai Changzheng Hospital between January 2019 and January 2022 after failure of first-line EGFR-TKIs. Of them, 39 received ICIs + chemotherapy and anti-angiogenic drugs (ICIs+BCP group), 51 received ICIs monotherapy (ICIs group), and 33 received chemotherapy and anti-angiogenic drugs (BCP group). The gender, age, smoking history, ECOG score, EGFR mutation type, PD-L1 TPS expression, and the first routine blood index before second-line treatment of all enrolled patients were recorded, and their clinical outcomes and prognosis factors were analyzed.There was no significant difference in the objective response rate (ORR) and disease control rate (DCR) between the three groups. Patients in ICIs+BCP group had better prognosis than those in ICIs monotherapy group (PFS:9.5 vs. 4.64 months, p<0.001; OS: 16.97 vs. 7.9 months p<0.001) or BCP group (9.5 vs. 6.48 months, p<0.005; OS: 16.97 vs. 11.39 months p<0.005).Our findings suggest that in the real-world practice in China, PD-1/L1 immune checkpoint inhibitors combined with chemotherapy and anti-angiogenic drugs are effective for the treatment of patients with advanced NSCLC who are resistant to EGFR-TKIs." @default.
- W4384695364 created "2023-07-20" @default.
- W4384695364 creator A5028364030 @default.
- W4384695364 creator A5028610394 @default.
- W4384695364 creator A5044677624 @default.
- W4384695364 creator A5048066442 @default.
- W4384695364 creator A5052140744 @default.
- W4384695364 date "2023-07-18" @default.
- W4384695364 modified "2023-10-14" @default.
- W4384695364 title "Real-world study of PD-1/L1 immune checkpoint inhibitors for advanced non-small cell lung cancer after resistance to EGFR-TKIs" @default.
- W4384695364 cites W2098674632 @default.
- W4384695364 cites W2104347254 @default.
- W4384695364 cites W2157824687 @default.
- W4384695364 cites W2198093519 @default.
- W4384695364 cites W2338576144 @default.
- W4384695364 cites W2538232731 @default.
- W4384695364 cites W2560367415 @default.
- W4384695364 cites W2572174216 @default.
- W4384695364 cites W2756422634 @default.
- W4384695364 cites W2771850922 @default.
- W4384695364 cites W2791290180 @default.
- W4384695364 cites W2803642760 @default.
- W4384695364 cites W2889653218 @default.
- W4384695364 cites W2907564726 @default.
- W4384695364 cites W2982085891 @default.
- W4384695364 cites W3000415041 @default.
- W4384695364 cites W3032822853 @default.
- W4384695364 cites W3088374074 @default.
- W4384695364 cites W3115349904 @default.
- W4384695364 cites W3154466284 @default.
- W4384695364 cites W4288459215 @default.
- W4384695364 cites W4310754365 @default.
- W4384695364 doi "https://doi.org/10.3389/fonc.2023.1217872" @default.
- W4384695364 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37534246" @default.
- W4384695364 hasPublicationYear "2023" @default.
- W4384695364 type Work @default.
- W4384695364 citedByCount "0" @default.
- W4384695364 crossrefType "journal-article" @default.
- W4384695364 hasAuthorship W4384695364A5028364030 @default.
- W4384695364 hasAuthorship W4384695364A5028610394 @default.
- W4384695364 hasAuthorship W4384695364A5044677624 @default.
- W4384695364 hasAuthorship W4384695364A5048066442 @default.
- W4384695364 hasAuthorship W4384695364A5052140744 @default.
- W4384695364 hasBestOaLocation W43846953641 @default.
- W4384695364 hasConcept C121608353 @default.
- W4384695364 hasConcept C126322002 @default.
- W4384695364 hasConcept C143998085 @default.
- W4384695364 hasConcept C167135981 @default.
- W4384695364 hasConcept C2776256026 @default.
- W4384695364 hasConcept C2776694085 @default.
- W4384695364 hasConcept C2778822529 @default.
- W4384695364 hasConcept C71924100 @default.
- W4384695364 hasConceptScore W4384695364C121608353 @default.
- W4384695364 hasConceptScore W4384695364C126322002 @default.
- W4384695364 hasConceptScore W4384695364C143998085 @default.
- W4384695364 hasConceptScore W4384695364C167135981 @default.
- W4384695364 hasConceptScore W4384695364C2776256026 @default.
- W4384695364 hasConceptScore W4384695364C2776694085 @default.
- W4384695364 hasConceptScore W4384695364C2778822529 @default.
- W4384695364 hasConceptScore W4384695364C71924100 @default.
- W4384695364 hasFunder F4320336620 @default.
- W4384695364 hasLocation W43846953641 @default.
- W4384695364 hasLocation W43846953642 @default.
- W4384695364 hasLocation W43846953643 @default.
- W4384695364 hasOpenAccess W4384695364 @default.
- W4384695364 hasPrimaryLocation W43846953641 @default.
- W4384695364 hasRelatedWork W1967103478 @default.
- W4384695364 hasRelatedWork W2032912323 @default.
- W4384695364 hasRelatedWork W2055244776 @default.
- W4384695364 hasRelatedWork W2348529436 @default.
- W4384695364 hasRelatedWork W2372561159 @default.
- W4384695364 hasRelatedWork W2375344515 @default.
- W4384695364 hasRelatedWork W2390152934 @default.
- W4384695364 hasRelatedWork W2413020017 @default.
- W4384695364 hasRelatedWork W2418204902 @default.
- W4384695364 hasRelatedWork W2569260518 @default.
- W4384695364 hasVolume "13" @default.
- W4384695364 isParatext "false" @default.
- W4384695364 isRetracted "false" @default.
- W4384695364 workType "article" @default.